Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27350809 | 0.85 | ADORA1 (0.68) | ADORA1ADORA2AADORA3CNR1SCN9A | |
| SCHEMBL20557489 | 0.80 | SMN1; SMN2 (0.53) | ADORA1ADORA2AADORA3NPC1RAB9A | |
| SCHEMBL4822464 | 0.79 | ADORA1 (1.00) | ADORA1ADORA2AADORA3NPC1RAB9A | |
| SCHEMBL19699609 | 0.77 | ADORA1 (0.73) | ADORA1ADORA2AADORA3NPC1RAB9A | |
| SCHEMBL24598576 | 0.77 | RAB9A (0.68) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6502989 | 0.76 | ADORA1 (1.00) | ADORA1ADORA2AADORA3 | |
| SCHEMBL15627410 | 0.76 | XIAP (0.51) | ADORA1ADORA2AADORA3RAB9AMEN1 | |
| SCHEMBL30028584 | 0.76 | ALDH1A1 (0.60) | ADORA1ADORA2AADORA3MEN1KMT2A | |
| SCHEMBL20557455 | 0.76 | ALDH1A1 (0.60) | ADORA1ADORA2AADORA3MEN1KMT2A | |
| SCHEMBL1861156 | 0.76 | XIAP (0.51) | ADORA1ADORA2AADORA3RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | ADORA1 4326/4885ADORA2A 3496/4885ADORA3 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.